2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1843 Real-world efficacy and cytomegalovirus-related complications of golidocitinib-based therapy in peripheral T-cell lymphoma

Jiangxue Hou, MD, Xudong Zhang, PhD2, Jian Zhou, PhD3, Yaomei Wang, PhD4, Xiaoli Yuan, PhD5, Keshu Zhou, PhD6, Xu Ji, PhD7, Lei Zhang, PhD8, HUIFANG ZHAO9, Jianwei Du, MS10, Ruihua Mi, MD, PhD11, Qinglan Zhang, MS12, Qingsong Yin, PhD13, chao Li, N/A14, Haiping Yang, N/A15, Yanzhen Guo, N/A16, Genjie Wang, N/A17, Kai Yue, N/A18, Xiaoqiang Zhao, N/A19, Jiayin Tong, MS20, Shiwei Yang, MS21, Baijun Fang, PhD22, Zunmin Zhu, MD23, Yanyan Liu, PhD24, quande Lin, PhD25
1 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
2 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
4 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
5 Henan Provincial People's Hospital, Zhengzhou, China
6 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
7 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
8 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
9 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
10 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
11 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
12 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
13 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
14 Nanyang Central Hospital, Nanyang, China
15 the First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China
16 the First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China
17 Shangqiu First People’s Hospital, Shangqiu, China
18 Nanyang Central Hospital, Nanyang, China
19 the First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China
20 the First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China
21 Henan Provincial People's Hospital, Zhengzhou, China
22 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
23 Henan Provincial People's Hospital, Zhengzhou, China
24 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
25 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

Background: Peripheral T-cell lymphoma (PTCL) is an aggressive malignancy with limited therapeutic options after relapse or progression. Golidocitinib, a selective JAK1 inhibitor, has demonstrated clinical activity in relapsed or refractory PTCL, but real-world evidence regarding its effectiveness and infection-related safety profile remains limited.

Methods: We conducted a multicenter retrospective study of patients with PTCL who received golidocitinib-based therapy between January 2023 and August 2025. Clinical activity was assessed according to disease status at golidocitinib initiation. Patients with non-complete remission disease at baseline constituted the primary response-evaluable population, whereas patients already in complete remission were analyzed separately as a remission-maintenance subgroup. Cytomegalovirus (CMV)-related events were evaluated among patients who underwent regular CMV DNA monitoring.

Results: Ninety-three patients were included. At data cutoff, 42 of 93 patients remained on golidocitinib without disease progression, whereas 51 had discontinued golidocitinib-based therapy. The median age was 57 years, and patients had received a median of 2 prior lines of therapy. Among 72 patients with non-complete remission disease at baseline, 47 achieved an objective response, including 20 complete responses and 27 partial responses, yielding an objective response rate of 65.3%. Among patients with baseline partial remission, 8 converted to complete remission. Among patients with progressive disease at treatment initiation, 12 achieved complete remission and 7 achieved partial remission. Median progression-free survival and overall survival were not reached; the estimated 12-month progression-free survival and overall survival rates were 60.5% and 75.9%, respectively. Overall, 88/93 (94.6%) patients experienced at least one adverse event, 70/93 (75.3%) experienced a grade 3 or higher adverse event, and none experienced treatment-related death. Given the known role of JAK1-mediated signaling in antiviral immunity, viral events were analyzed in greater detail. Thirty EBV-related event was observed. Among 48 patients who underwent regular CMV DNA monitoring, 17 developed CMV-related events, corresponding to an incidence of 35.4% in the monitored cohort, including CMV viremia, probable CMV pneumonia, and CMV retinitis. Eight patients had CMV viremia, 8 developed probable CMV pneumonia, and 4 developed CMV retinitis. Eight patients had concurrent EBV infection or reactivation. Among 4 patients with CMV retinitis, 2 recovered normal vision, whereas 2 had persistent severe visual impairment despite antiviral treatment. In multivariable analysis, involvement of at least two extranodal sites was associated with increased risk of CMV-related events.

Conclusions: Golidocitinib-based therapy showed clinically meaningful real-world activity across distinct treatment contexts, including salvage therapy, response deepening, and remission maintenance. CMV-related events were frequent among monitored patients and included vision-threatening retinitis. These findings support risk-adapted viral and ophthalmologic surveillance during selective JAK1 inhibition.

Jiangxue Hou, MD: No relevant conflicts of interest to declare.